Over 180 companies claim to provide services for the development of companion diagnostic tests
Added: (Fri Aug 06 2021)
Pressbox (Press Release) -
It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).
To order this 320+ page report, which features 120+ figures and 115+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html
The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:
Type of Service Offered
Feasibility Studies
Assay Development
Analytical Validation
Clinical Validation
Type of Assay Technique Used
in situ hybridization / Immunohistochemistry
Next Generation Sequencing
Polymerase Chain Reaction
Others
Key geographical regions
North America
Europe
Asia Pacific
To request for sample - https://www.rootsanalysis.com/reports/297/request-sample.html
The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:
Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
Paul Kortschak (Senior Vice President, Novodiax)
Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Profiles
6. Partnerships and Collaborations
7. Likely Partner Analysis
8. Company Competitiveness Analysis
9. Stakeholder Needs Analysis
10. Value Chain Analysis
11. Clinical Research on Cancer Biomarkers: Big Pharma Perspective
12. Market Forecast And Opportunity Analysis
13. Executive Insights
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis